Get notified when KODK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Asset Impairment (new) — Kodak recorded a $22 million impairment charge on its Wildcat Discovery Technologies investment in 2025 due to strategic challenges at the portfolio company.
Kodak completes pharma facility, cuts 10% of workforce, exchanges Series C for equity
Filed March 12, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 17, 2025 · ~1 min read
Key Changes
-
high
Series C Preferred Stock fully exchanged for 15.1M common shares in August 2025, eliminating dividend obligations; Series B terms amended with June 2029 mandatory redemption and conversion triggers at $14.50-$16.50 stock prices.
Notes: Preferred Stock verify on EDGAR → -
high
Term Loan lenders require $100M in prepayments ($50M by March 18, 2026 and $50M by June 1, 2026), each with 1% fee, signaling lender pressure to reduce exposure.
Notes: Term Loan Amendment verify on EDGAR → -
high
Workforce reduced 10% from 3,900 to 3,500 employees and operations pulled back from two countries, reflecting cost management or restructuring amid tariff and pricing pressures.
Business: Headcount verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (TRV 10-Q) is open in full — no account needed.
Partner
Trade KODK commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify